Pemvidutide's Phase 3 PERFORMA readout will determine whether BTD-backed MASH efficacy translates to registrational success in a crowded field

Bull

A positive outcome would be statistically significant improvement on biopsy-based co-primary endpoints — fibrosis improvement without worsening of MASH and/or MASH resolution without worsening of fibrosis — consistent with or exceeding the ELF and LSM signals seen at 48 weeks in IMPACT Phase 2b. Combined with a clean tolerability profile and low discontinuation rates (as seen in Phase 2b), this would support accelerated approval and validate pemvidutide as a differentiated entrant in MASH, potentially commanding significant commercial positioning given the BTD-facilitated FDA dialogue already completed.

Bear

The most likely failure modes are: biopsy-based endpoints failing to reach statistical significance despite non-invasive biomarker improvements (ELF and LSM may not fully predict histological response), dose-limiting tolerability issues emerging at scale across a global trial population, or the fibrosis signal seen in Phase 2b proving insufficient relative to the higher bar set by competitors who have already published registrational-quality histological data. A partial result — MASH resolution without fibrosis benefit, or vice versa — could also undermine the label breadth needed for competitive differentiation.